Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18222999 | 0.88 | ALDH1A1 (0.67) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL10542963 | 0.83 | ALDH1A1 (1.00) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL1563556 | 0.81 | ALDH1A1 (0.59) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL1563011 | 0.81 | ALDH1A1 (0.59) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL2524844 | 0.77 | ALDH1A1 (0.61) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL1563600 | 0.76 | ALDH1A1 (0.69) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL2523003 | 0.75 | ALDH1A1 (0.58) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL8358160 | 0.75 | ALDH1A1 (0.50) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL2522823 | 0.74 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL2527646 | 0.74 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2NPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2023051495-A1 | ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS, AND COMPOSITION AND USE THEREOF | 中山医诺维申新药研发有限公司 | 2023-04-06 | — | — | WO | disclosed |
| CN-115873000-A | Isoquinolone and quinazolinone compounds, and composition and application thereof | 中山医诺维申新药研发有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-3277673-B1 | TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3277673-B1 | TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210130361-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | disclosed |
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | disclosed |
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| CN-1951939-A | Novel pyrrole derivatives as pharmaceutical agents | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| CN-1269820-C | Novel pyrrole derivatives as medicaments | LILLY CO ELI (US) | 2006-08-16 | — | — | CN | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1567528-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| CN-1511157-A | Novel pyrrole derivatives as medicaments | — | 2004-07-07 | — | — | CN | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822337-B2 | TGF-β inhibitorC | TGFBR1, TGFBR2, TGFB1 | ALDH1A1 1989/4885RAB9A 3428/4885SMN1; SMN2 2617/4885 |
| US-20210130361-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | ALDH1A1 1295/4885RAB9A 2799/4885SMN1; SMN2 2991/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | ALDH1A1 2217/4885RAB9A 2005/4885SMN1; SMN2 4655/4885 |
| US-20180086764-A1 | TGF-ß Inhibitors | TGFBR1, TGFBR2, TGFB1 | ALDH1A1 1295/4885RAB9A 2799/4885SMN1; SMN2 2991/4885 |
| US-20230123591-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | ALDH1A1 1295/4885RAB9A 2799/4885SMN1; SMN2 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.